Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD by Price, David et al.
© 2011 Price et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Asthma and Allergy 2011:4 37–47
Journal of Asthma and Allergy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
37
OriginAL reseArch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/JAA.S17709
effectiveness of inhaler types for real-world 
asthma management: retrospective observational 
study using the gPrD
David Price1,2 
John haughney1 
erika sims2 
Muzammil Ali2 
Julie von Ziegenweidt2 
elizabeth V hillyer2 
Amanda J Lee3 
Alison chisholm2 
neil Barnes4
1centre of Academic Primary care, 
University of Aberdeen, Aberdeen, UK; 
2research in real Life Ltd, cawston, 
norwich, UK; 3section of Population 
health, University of Aberdeen, UK; 
4Department of respiratory Medicine, 
London chest hospital, Barts and The 
London nhs Trust, London, UK
correspondence: David Price 
centre of Academic Primary care, 
University of Aberdeen, Foresterhill 
health centre, Westburn road,  
Aberdeen AB25 2AY, scotland, UK 
Tel +44 1224 554588 
Fax +44 1224 550683 
email david@respiratoryresearch.org
Purpose: Results of randomized controlled trials may not predict effectiveness of inhaled 
corticosteroids (ICS) in real-world clinical practice, where inhaler technique and device 
characteristics can influence effectiveness. We compared asthma outcomes for ICS delivered 
via three different inhaler devices: pressurized metered-dose inhaler (pMDI), breath-actuated 
MDI (BAI), and dry powder inhaler (DPI).
Patients and methods: This retrospective database study evaluated 1-year outcomes for 
primary care patients with asthma aged 5–60 years prescribed their first ICS (initiation population) 
by pMDI (n = 39,746), BAI (n = 9809), or DPI (n = 6792), or their first ICS dose increase (step-up 
population) by pMDI (n = 6245), BAI (n = 1388), or DPI (n = 1536). Co-primary outcome 
measures were composite proxy measures of asthma control (no hospital attendance for asthma, 
oral corticosteroids, or antibiotics for lower respiratory infection) and severe exacerbations 
(unscheduled hospital admission, emergency room attendance, or oral corticosteroids). Outcomes 
were adjusted for potential confounding factors identified during a baseline year.
Results: In the initiation population, adjusted odds ratios (95% confidence intervals [CI]) for 
asthma control, as compared with pMDIs, were significantly better for BAIs (1.08 [1.02–1.14]) and 
DPIs (1.13 [1.06–1.21]), while adjusted exacerbation rate ratios (95% CI) were 1.00 (0.93–1.08) 
and 0.88 (0.81–0.95), respectively. In the step-up population, adjusted odds of asthma control 
were 1.21 (1.05–1.39) for BAIs and 1.13 (0.99–1.29) for DPIs; adjusted exacerbation rate ratios 
were 0.83 (0.71–0.98) for BAIs and 0.85 (0.74–0.98) for DPIs, compared with pMDIs.
Conclusion: Inhaler device selection may have a bearing on clinical outcomes. Differences 
in real-world effectiveness among these devices require closer evaluation in well-designed 
prospective trials.
Keywords: asthma control, dry powder inhaler, breath-actuated inhaler, metered-dose inhaler, 
primary care
Introduction
The findings of randomized controlled trials (RCTs) are integral to establishing the 
efficacy of therapies but may not predict their effectiveness in a real-world clinical 
setting, because RCTs are designed to maximize internal validity. Therefore, strict RCT 
inclusion criteria typically select idealized patient populations, free of comorbidities and 
with good adherence, and RCT protocols tend to require close patient monitoring at a 
level rarely possible or achieved in everyday clinical practice. Over 90% of patients with 
asthma in the community, such as those who smoke or have limited airway reversibility, 
do not meet eligibility criteria for most RCTs of asthma therapies.1,2
Several authors have expressed concern about the limited external validity, or 
generalizability, of many RCTs,1–5 and there remains a need for effectiveness data to Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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complement RCT findings. The use of diverse approaches 
to determine the appropriate use of therapeutic interventions 
is advocated by Rawlins5 to replace an evidence hierarchy 
placing RCT results at the pinnacle of importance. Rigorously 
conducted observational studies can provide evidence to 
supplement that from RCTs.
Real-life data is particularly pertinent for inhaled 
therapies, for which additional factors such as delivery 
device characteristics and inhaler technique come into play 
and can influence the effectiveness of therapy.6 Reviews of 
RCTs comparing asthma inhaler devices report no significant 
differences in clinical effectiveness according to device type.7–9 
However, patients enrolled in these trials usually received 
inhaler training and had to demonstrate and maintain proper 
inhaler technique throughout the trials. Yet in the real world, 
patients frequently make mistakes when using their inhaler 
devices,6,10–13 and errors in use of corticosteroid inhalers have 
been associated with poor asthma control.14 Moreover, most 
inhaler RCTs are short term, and there is some evidence that, 
in the real world, inhaler technique deteriorates over time.6 
Indeed, results of an earlier observational study using a large 
primary care medical record database suggest that inhaler 
device choice does in fact affect asthma outcomes.15
The objective of this retrospective database study was 
to compare outcomes for patients with asthma who were 
prescribed their first inhaled corticosteroid (ICS) therapy or 
an increase in ICS dose via pressurized metered-dose inhaler 
(pMDI), breath-actuated MDI (BAI), or dry powder inhaler 
(DPI). We examined respiratory-related clinical endpoints 
combined in composite measures of asthma control and 
exacerbations.
Methods
This 2-year retrospective observational study comprised a 
baseline year for defining cohorts and potential confounding 
factors, followed consecutively by an outcome year starting 
on the index date when patients received a prescription for 
first ICS or an increase in dose of ICS. The data source for the 
study was the General Practice Research Database (GPRD), 
a large computerized database containing de-identified 
longitudinal medical record data from over 450 participating 
general practices located throughout the United Kingdom 
(UK), including England, Scotland, Wales, and Northern 
Ireland.16 The GPRD is well-validated and has been used 
frequently for respiratory research.17–20
Medical records from the GPRD were examined for a 
10.5-year period when all inhaler devices of interest were 
available, beginning January 1997 and ending June 30, 2007. 
Patients with asthma and aged 5–60 years on the index 
date were included in the study if they were continuously 
  registered at the same practice for at least 2 years including 
the 12 months before and 12 months after the index date; 
and the practice had to be judged by the GPRD as having 
up-to-standard data during that time.16 Evidence of asthma 
was defined as a recorded diagnosis of asthma or two or more 
prescriptions for ICS for asthma at more than one time point 
during the outcome year. Prescribing information recorded 
in the GPRD includes dosage, quantity, indication, and 
instructions. Patients were excluded if their record contained a 
diagnostic code for chronic obstructive pulmonary disease or 
any chronic respiratory condition other than asthma or if they 
were prescribed more than one ICS or a combination inhaler 
with long-acting β2 agonist (LABA) on the index date.
Two separate analyses were undertaken for 1) those 
patients receiving a first ICS prescription (initiation popula-
tion) and 2) those receiving an increased dose of ICS (step-up 
population), the latter having at least one recorded prescrip-
tion for ICS during the baseline year. Patients were included 
if they received ICS using only one device type, namely, a 
pMDI, BAI, or DPI, during the outcome year. Cost effective-
ness analyses were also carried out for both the initiation and 
step-up populations, but these data are not the focus of this 
paper and are published separately.21
The GPRD Independent Scientific Advisory Committee 
approved the use of GPRD data for this study.
Outcome measures
All outcomes were predefined before reviewing the data. The 
two co-primary outcome measures were a proxy for asthma 
control and severe exacerbation rate. The “primary measure 
of asthma control” was a composite endpoint, defined as 
including all of the following:
1.  no recorded hospital attendance for asthma (neither 
admission nor attendance at the emergency department, 
the outpatient department, or out of hours);
2.  no prescription for oral corticosteroids (acute or 
  maintenance); and
3.  no consultations, hospital admissions, or emergency 
department attendance for lower respiratory tract 
  infection requiring antibiotics.
A severe asthma exacerbation was defined, in line with 
a recent ATS/ERS task force definition,22 as unscheduled 
hospital admission or emergency department attendance for 
respiratory disease or a prescription for oral corticosteroids. 
Exacerbations on the index date were included within the 
outcome data.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Secondary outcomes included another composite measure, 
“asthma control plus short-acting β2 agonist (SABA) use”, 
which factored the additional criterion of minimal reliever 
medication use into the co-primary control proxy (ie, control 
required a maximum average daily use of 200 µg albuterol 
or 500 µg terbutaline). Other secondary endpoints were the 
disaggregated outcomes comprising the composite measures 
and changes in therapy, including increase in ICS dose or 
use of additional therapy.
The ICS doses are reported ex-valve as the chlorofluorocarbon-
beclomethasone (CFC-BDP)-equivalent, with doses of 
budesonide (BUD), fluticasone propionate (FP), BDP 
in solution (Qvar®, Teva UK), and mometasone (MOM) 
  converted as necessary in the following dose ratios relative to 
CFC-BDP: CFC-BDP:BUD:FP:Qvar:MOM = 1:1:2:2:2.
statistical analyses
Descriptive statistics were used to compare baseline factors 
among cohorts. The Kruskal–Wallis test was used to compare 
skewed continuous data between cohorts whilst the χ2 test 
was used to compare categorical factors.
Patients prescribed pMDIs were defined as the reference 
cohort, and patients prescribed BAIs or DPIs as the com-
parison cohorts. Results were examined separately for each 
population (initiation and step-up populations) during the 
outcome year, the primary period of analysis. All analyses 
were specified a priori.
Odds ratios for the dichotomized definitions of asthma 
control were calculated using a binary logistic regression 
model with control as the dependent variable and cohort, 
together with potential confounding factors (year of index 
date, age, sex, socioeconomic status, and comorbidity and 
treatment with medication that could affect   respiratory 
outcomes), as explanatory variables. Socioeconomic 
  status was that assigned, in quintiles, by the GPRD to each 
  practice using the Index of Multiple Deprivation as a proxy 
measure. The GPRD has linked the socioeconomic status 
to small areas using the practice postcode where possible. 
Comorbidities were included via the Charlson comorbidity 
index score,23 a weighted index that accounts for number and 
severity of comorbidities, as calculated for each patient using 
ICD-9 matching algorithms produced by CliniClue software 
(http://www.cliniclue.com/software).
The selected confounding factors were variables that 
were significantly different (P , 0.10) between cohorts at 
baseline.
The total number of severe exacerbations in the outcome 
period was compared between cohorts using a Poisson 
regression model to obtain estimates of exacerbation rates 
relative to the pMDI cohort. The model was adjusted for 
over-dispersion using robust standard errors and adjustments 
for potential baseline confounders.
Data were analyzed using SPSS version 17 (SPSS, 
Chicago, IL, USA), and differences between cohorts 
were considered to be significant if P , 0.05 and trends if 
0.05 # P , 0.10.
Results
Figure 1 depicts the identification of eligible patients in the 
GPRD who received a first prescription for ICS or increased 
dose of ICS. Baseline characteristics and asthma-related 
medical resource use of patients in the three cohorts of 
the initiation and step-up populations are summarized in 
Tables 1 and 2.
Patients receiving a first prescription  
for ics: initiation population
There were several statistically significant but small baseline 
differences among the three cohorts (Tables 1 and 2). Given 
the minimal clinical significance of these differences, as 
adjudicated by clinicians in the research team, these factors 
were handled through statistical modeling, which allowed 
adjustment of outcomes for potential confounding factors 
rather than necessitating subgroup or matched analysis.
The dose of ICS prescribed at the index date was 
significantly different among the three cohorts, with the 
same median dose in all three (400 µg/day), and wider 
variability in the BAI and DPI cohorts (Table 3). Spacers 
were prescribed to 17.7%, 4.0%, and 0.7% of patients in 
pMDI, BAI, and DPI cohorts, respectively. A statistically 
significant, but clinically small, difference in ICS dose 
as received (based on prescriptions dispensed over the 
12-month period) was also evident during the outcome year 
(see Table 3). Thus, the profile of dosing across the treatment 
cohorts was fairly similar in terms of actual use, with some 
differences in proportions of patients prescribed the lowest 
starting doses.
The adjusted odds ratios for asthma control during 
the outcome year were significantly greater for patients 
  prescribed a BAI or DPI relative to those prescribed a pMDI 
(Figure 2). The adjusted rate ratio for severe exacerbations 
was significantly lower in the DPI, but not the BAI, cohort, 
relative to the pMDI cohort (Figure 2).
When restricted SABA use was added to the composite 
measure, the odds ratios for asthma control plus SABA 
use significantly favored patients in BAI and DPI cohorts Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Table  3  Inhaled  corticosteroid  type  and  doses  prescribed  for  and  used  by  patients  receiving  a  first  prescription  or  increased 
dose of ics
Initiation population (N = 56,347)
pMDI  
(N = 39,746)
BAI  
(N = 9809)
DPI  
(N = 6792)
P-value
ics prescribed at the index date
  Beclomethasonea 33,926 (85.4) 8750 (89.2) 1468 (21.6) –
  Qvar 2938 (7.4) 1059 (10.8) 0 (0)
  Fluticasone 1473 (3.7) 0 (0) 788 (11.6)
  Mometasone  0 (0) 0 (0) 39 (0.6)
  Budesonide  1380 (3.5) 0 (0) 4497 (66.2)
  ciclesonide  29 (0.1) 0 (0) 0 (0)
ics dose prescribed at index date
  Median (iQr) 400 (400–400) 400 (200–400) 400 (200–800) ,0.001
  1–200 µg/day 8223 (20.7) 2981 (30.4) 1999 (29.4) ,0.001
  201–400 µg/day 24,230 (61.0) 5366 (54.7) 2816 (41.5)
  401–800 µg/day 5333 (13.4) 941 (9.6) 1523 (22.4)
  $800 µg/day 1960 (4.9) 521 (5.3) 454 (6.7)
ics dose used over outcome yearb
  Median (iQr) 137 (55–274) 142 (55–274) 110 (55–252) ,0.001
  1–200 µg/day 24,398 (61.4) 5987 (61.0) 4602 (67.8) ,0.001
  201–400 µg/day 9497 (23.9) 2368 (24.1) 1318 (19.4)
  401–800 µg/day 4391 (11.0) 1131 (11.5) 673 (9.9)
  $800 µg/day 1455 (3.7) 322 (3.3) 191 (2.8)
Step-up population (N = 9169)
pMDI  
(N = 6245)
BAI  
(N = 1388)
DPI  
(N = 1536)
P-value
ics dose used over baseline yearb
  1–200 µg/day 4463 (71.5) 1042 (75.1) 1103 (71.8) 0.008
  201–400 µg/day 1150 (18.4) 237 (17.1) 264 (17.2)
  401–800 µg/day 487 (7.8) 83 (6.0) 116 (7.6)
  $800 µg/day 145 (2.3) 26 (1.9) 53 (3.5)
ics prescribed at the index date
  Beclomethasonea 4499 (72.0) 1205 (86.8) 308 (20.1) –
  Qvar 442 (7.1) 183 (13.2) 0 (0)
  Fluticasone 1028 (16.5) 0 (0) 382 (24.9)
  Mometasone  0 (0) 0 (0) 32 (2.1)
  Budesonide  274 (4.4) 0 (0) 814 (53.0)
  ciclesonide  2 (0) 0 (0) 0 (0)
ics dose prescribed at index date
  Median (iQr) 800 (400–1000) 500 (400–1000) 800 (400–1000) ,0.001
  1–200 µg/day 221 (3.5) 67 (4.8) 64 (4.2) ,0.001
  201–400 g/day 2068 (33.1) 620 (44.7) 469 (30.5)
  401–800 µg/day 2103 (33.7) 351 (25.3) 606 (39.5)
  $800 µg/day 1853 (29.7) 350 (25.2) 397 (25.8)
ics dose used over outcome yearb
  Median (iQr) 329 (164–658) 301 (164–548) 274 (142–548) ,0.001
  1–200 µg/day 1700 (27.2) 439 (31.6) 575 (37.5) ,0.001
  201–400 µg/day 1727 (27.7) 392 (28.2) 430 (28.0)
  401–800 µg/day 1571 (25.2) 365 (26.3) 317 (20.7)
  $800 µg/day 1246 (20.0) 192 (13.8) 211 (13.8)
Notes: Values shown are n (%) or median (interquartile range). P-values for comparison among the three cohorts calculated with χ2 test for categorical data, Kruskal–Wallis test 
for continuous data; The ICS doses are reported as the chlorofluorocarbon-beclomethasone (CFC-BDP)-equivalent, with doses of budesonide (BUD), fluticasone propionate 
(FP), BDP in solution (Qvar®, Teva UK), and mometasone (MOM) converted as necessary in the following dose ratios relative to cFc-BDP: cFc-BDP:BUD:FP:Qvar: 
MOM = 1:1:2:2:2; aBeclomethasone included mostly CFC-BDP, as large-particle hydrofluoroalkane (HFA)-beclomethasone became available towards the end of the study; 
bThe ics doses used over the baseline and outcome years were calculated as the dispensed amount divided by 365.
Abbreviations: BAi, breath-actuated inhaler; DPi, dry powder inhaler; ics, inhaled corticosteroid; pMDi, pressurized metered-dose inhaler.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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(Any patient who commenced
inhaled corticosteroid therapy)
N = 156,003
Patients with valid
inclusion criteria
N = 56,347 
1) Asthma diagnosis or
    current asthma therapy in
    year after
2) No COPD diagnosis
3) Start date ≥ 1997 
4) Age from 5–60 years
5) No other chronic
    respiratory diseases 
6) Started on single ICS
7) Up-to-standard data
    during 1 year before and
    1 year after index date
Reasons for exclusion: 
N = 99,656 
1) COPD diagnosis = 48,467
2) Age < 5 or > 60 = 20,254
3) Start date < 1997 = 28,323 
4) No asthma diagnosis and
    no asthma therapy in year 
    after = 2273 
5) Other chronic pulmonary
    disease diagnosis = 173
6) Started on multiple ICS = 166
STEP-UP POPULATION  
(Any patient with first dose increase
of ≥ 50% in inhaled corticosteroid) 
N = 27,396 
Patients with valid inclusion
criteria
N = 9169 
1) Asthma diagnosis or current
    asthma therapy in year after
2) No COPD diagnosis
3) Start date ≥ 1997 
4) Age from 5–60 years
5) No other chronic respiratory
    diseases
6) Started on single ICS
7) Up-to-standard data during 1
    year before and 1 year after
    index date
Reasons for exclusion: 
N = 18,227 
1) COPD diagnosis = 8269
2) Age < 5 or > 60 = 3185
3) Start date < 1997 = 6197
4) Combination inhaler in
    baseline year = 129 
5) No asthma diagnosis and
    no asthma therapy in year 
    after = 219 
6) Other chronic pulmonary
    disease diagnosis = 28
7) Started on multiple ICS = 200
Patients commencing inhaled
corticosteroid via:
pMDI N = 39,746 (70.5%) 
BAI N = 9809 (17.4%) 
DPI N = 6792 (12.1%) 
N = 56,347 
Patients who received their first
database-recorded dose increase
of inhaled corticosteroid via:
pMDI N = 6245 (68.1%) 
BAI N = 1388 (15.1%) 
DPI N = 1536 (16.8%) 
N = 9169 
INITIATION POPULATION
Figure 1 selection of eligible patients in the database. 
Abbreviations: BAi, breath-actuated inhaler; cOPD, chronic obstructive pulmonary disease; DPi, dry powder inhaler; ics, inhaled corticosteroid; pMDi, pressurized 
metered-dose inhaler.
(Figure 2). Results for disaggregated outcomes of the 
composite measures and percentages of patients with change 
in therapy are depicted in Table 4.
Patients receiving an increased dose  
of ics: step-up population
As for the initiation population, baseline characteristics and 
measures that were statistically significantly different among 
the three cohorts (Tables 1 and 2) were included in the out-
come analyses as potential confounding factors.
The median dose of ICS on the index date was   lowest in 
the BAI cohort (500 vs 800 µg/day in the other two cohorts), 
and proportionately more patients in the BAI cohort were 
prescribed a dose of 201–400 µg/day, with the same 
  interquartile range for dose in all three cohorts (Table 3). 
  Spacers were prescribed to 12.8%, 1.5%, and 0.8% of 
patients in pMDI, BAI, and DPI cohorts, respectively. As 
for the initiation population, while differences in ICS doses 
among the cohorts were statistically significant, the profile 
of doses received across the treatment cohorts was fairly 
similar, with the highest median ICS dose used in the pMDI 
cohort, which included proportionately more patients who 
received a dose $800 µg/day.
Over the outcome year, the adjusted odds of asthma 
control was significantly greater in the BAI cohort than in 
the pMDI cohort, while the odds for the DPI cohort was 
not significantly different when adjusted for confounders 
(Figure 2). The adjusted rate ratios for severe exacerbations 
were significantly lower for both BAI and DPI cohorts 
(Figure 2).
There were no significant differences among cohorts in 
the odds for asthma control plus SABA use (Figure 2). Other 
secondary outcomes are summarized in Table 4.
Discussion
For the real-world primary care patients included in this 
database analysis, the odds of achieving our a priori 
definition of asthma control during the outcome year were 
  significantly better for patients initiating ICS therapy via 
BAI or DPI compared with a pMDI, and for those receiving 
an ICS dose increase via BAI compared with a pMDI. The 
co-primary outcome measure, rate of severe exacerbations, Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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was   significantly lower for those in the initiation population 
using a DPI and for those in the step-up population using a 
BAI or DPI, again as compared with a pMDI.
The goal of this study was to assess whether or not 
the asthma inhaler device is of material importance in the 
  prescribing of ICS to patients in a real-world setting. The 
study results suggest that the inhaler device does in fact 
matter. Findings were generally consistent for BAIs and 
DPIs when compared with pMDIs and as prescribed for 
both initiation and step-up populations. Overall, the signal 
was stronger – in terms of the two co-primary outcome 
  measures – with a DPI for patients initiating ICS and with a 
BAI for patients prescribed an increased dose of ICS.
BAI
DPI
Primary measure of asthma controla
Asthma control plus SABA useb
Severe exacerbation ratec
0.8 0.9 1 1.1 1.2 1.3
Adjusted odds or rate ratio (95% CI)
Figure 2 Odds ratios (95% ci) for achieving the composite measures of asthma 
control and rate ratio (95% ci) for severe exacerbations during the outcome year 
for patients who received a prescription for first ICS (top panel) or increased dose 
of ics (bottom panel) using a BAi or DPi, with pMDi cohort as comparator. 
Notes:  Adjustments  were  made  for  following  baseline  parameters:  asex,  age, 
gerD  diagnosis,  nsAiDs,  acetaminophen,  asthma  consultations  excluding  oral 
steroids, antibiotics, oral steroid prescriptions, ics dose at index date, year of index 
date;  bgerD diagnosis, nsAiDs, acetaminophen, asthma consultations excluding 
oral steroids, sABA dose, antibiotics, oral steroid prescriptions, hospital asthma 
definite, ICS dose at index date, year of index date; cAge, nsAiDs, acetaminophen, 
asthma consultations excluding oral steroids, sABA dose, antibiotics, oral steroid 
prescriptions,  hospital  admissions,  year  of  index  date,  ics  dose  at  index  date; 
dsex,  nsAiDs,  acetaminophen,  baseline  sABA  dose,  antibiotics,  oral  steroid 
prescriptions,  ics  dose  at  index  date;  eAcetaminophen,  asthma  consultations 
excluding oral steroids, sABA dose, antibiotics, oral steroid prescriptions, ics dose 
at index date;  fsex, nsAiDs, asthma consultations excluding oral steroids, sABA 
dose, antibiotics, oral steroid prescriptions, average baseline ics dose. 
Abbreviations:  BAi,  breath-actuated  inhaler;  BMi,  body  mass  index;  DPi,  dry 
powder inhaler; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; 
NSAIDs, nonsteroidal anti-inflammatory drugs; pMDI, pressurized metered-dose 
inhaler; sABA, short-acting β2 agonist.
BAI
DPI
Primary measure of asthma controld
Asthma control plus SABA usee
Severe exacerbation ratef
1 0.60 .7 0.8 0.9 1.1 1.2 1.3 1.4 1.5 1.6
Adjusted odds or rate ratio (95% CI)
While results of RCTs indicate little difference in the 
effectiveness of inhaler devices when used correctly and 
predominantly over the short-term,8,9 our findings suggest 
that real-world factors influence the effectiveness of these 
devices. Correct inhaler use is integral to the effectiveness 
of inhaled therapy,6,24–26 and it is possible that correct use is 
easier to learn and maintain with BAIs and DPIs than with 
pMDIs. Other factors that could influence effectiveness of 
therapy include adherence to therapy, patient preferences, 
and physician practices and preferences. As reflected in 
the prescribing patterns captured by this study, pMDIs are 
the most commonly prescribed inhaler devices in the UK, 
perhaps in part because they have been available for longer. 
Thus, another possible explanation for the observed differ-
ences, purely speculative, is that patients prescribed a BAI 
or DPI rather than a pMDI constitute a particular subgroup 
of patients in the view of their physicians and thus are moni-
tored more closely, with resultant better outcomes, than those 
prescribed the more common pMDIs.
The delivery of medication to the target airways from an 
inhaler device depends on proper preparation of the device 
coupled with correct inhalation technique, both of which are 
device-specific. The correct use of pMDIs requires actuation 
of the dose synchronized with an inhalation that is slow and 
deep; and the most common mistakes made with pMDIs are 
failure to coordinate actuation with inhalation and too rapid 
an inhalation.6,25,26 By contrast, dose emission from both 
BAIs and DPIs is actuated by the patient’s inhalation, which 
should be slow and deep for a BAI and, for a DPI, sharp and 
forceful to aerosolize the dry powder. Some patients may 
not be able to achieve sufficient inspiratory flow to actuate 
certain types of DPI.27 Failure to exhale before actuation 
and to breath-hold after inhalation are mistakes common 
to all devices.10,12
Observational studies evaluating patients’ abilities to use 
inhaler devices correctly show inconsistent results, with some 
reporting mistakes to be more common with pMDIs than 
DPIs and BAIs11,12 and others reporting similar prevalence of 
inhaler misuse with pMDIs and DPIs.13,28 While   coordination 
of actuation and inhalation is a recognized challenge with 
pMDIs and many consider these to be a difficult device to 
use,6 all inhaler device types have specific requirements 
for proper preparation and use. Measures that can promote 
  correct inhaler technique include provision of inhaler device 
training, repeat training with each revisit, and prescribing 
of the same type of inhaler device for both controller and 
reliever medications.25,26 Moreover, patients may have   natural 
inspiratory patterns that accommodate one device better Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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than another; this should be taken into consideration when 
choosing the inhaler type.25
The strengths of this study include the large numbers of 
patients with available data from a validated data source. 
The 12-month outcome period minimized the effect of 
seasonal changes and allowed us to record measurable dif-
ferences in less frequent outcomes such as severe asthma 
exacerbations. Study outcome measures were chosen 
prospectively. Because of the large patient numbers, even 
baseline differences among inhaler cohorts that were small 
from a clinical perspective were often statistically signifi-
cantly different. We included baseline characteristics that 
were statistically significantly different among the three 
cohorts as potential confounding factors in the outcome 
analyses.
Severe exacerbations were identified in the database 
using two parameters proposed by a recent joint task 
force of the American Thoracic Society and European 
  Respiratory Society to define exacerbations,22 namely, 
unplanned or emergency care for asthma or a course of 
oral corticosteroid, both   markers of poor asthma control. 
The primary measure of asthma control was a composite 
proxy that   captured the absence in the database of recorded 
exacerbations or lower respiratory tract infection requiring 
antibiotics. The requirement for no recorded antibiotics for 
lower   respiratory infection was based on the rationale that 
asthma exacerbations can be confused clinically for respi-
ratory infection.29,30 A weakness of this proxy measure is 
evident in that three quarters (76%) and over half (61%) of 
patients in the initiation and step-up populations, respec-
tively, met the primary asthma control definition during the 
baseline year before their health-care provider prescribed 
first ICS or an increased dose of ICS. Of course, the asthma 
control measure was not designed to supply information 
for a specific point in time, such as the date of the index 
prescription, but rather to summarize clinical information 
for a 1-year period.
The secondary composite measure was designed to add 
another aspect of asthma control to the primary outcome 
measure, namely, prescriptions for reliever therapy (SABA) 
as an indicator of asthma symptoms. The adjusted results for 
this measure significantly favored the BAI and DPI cohorts 
in the initiation but not the step-up population, as compared 
with the pMDI cohorts. We do not have a ready explanation 
for this difference between populations but note that SABA 
prescriptions are an imprecise measure of actual SABA use,22 
Table 4 Outcomes for patients initiating ics or receiving an increased dose of ics via pressurized metered-dose inhaler, breath-actuated 
inhaler, or dry powder inhaler
Initiation population (N = 56,347) Step-up population (N = 9169)
pMDI  
(N = 39,746)
BAI  
(N = 9809)
DPI  
(N = 6792)
P-value pMDI  
(N = 6245)
BAI  
(N = 1388)
DPI  
(N = 1536)
P-value
Asthma control status
    Primary measure of  
asthma control
29,961 (75.4) 7518 (76.6) 5307 (78.1) 4237 (67.8) 1032 (74.4) 1103 (71.8)
    Asthma control plus  
sABA use
21,956 (55.2) 5605 (57.1) 4185 (61.6) 2289 (36.7) 584 (42.1) 610 (39.7)
severe asthma exacerbations
 0 33,799 (85.0) 8366 (85.3) 5918 (87.1) 4840 (77.5) 1144 (82.4) 1254 (81.6)
 1 4407 (11.1) 1061 (10.8) 658 (9.7) 850 (13.6) 166 (12.0) 180 (11.7)
 2 978 (2.5) 255 (2.6) 131 (1.9) 310 (5.0) 52 (3.7) 55 (3.6)
 $ 3 562 (1.4) 127 (1.3) 85 (1.3) 245 (3.9) 26 (1.9) 47 (3.1)
Disaggregated outcomes of the composite measures:
$1 oral corticosteroid course 5938 (14.9) 1442 (14.7) 874 (12.9) 0.001 1400 (22.4) 242 (17.4) 282 (18.4) ,0.001
$1 hospital attendance 26 (0.1) 14 (0.1) 0 (0) 0.002 16 (0.3) 2 (0.1) 2 (0.1) 0.519
$1 course of antibiotics  
for LrTi
5079 (12.8) 1145 (11.7) 798 (11.7) 0.003 970 (15.5) 177 (12.8) 219 (14.3) 0.108
Mean sABA dose . 200 µg/daya 11,832 (29.8) 2779 (28.3) 1605 (23.6) ,0.001 3152 (50.5) 661 (47.6) 739 (48.1) 0.066
change in or additional therapy 5501 (13.8) 1583 (16.1) 1099 (16.2) ,0.001 1693 (27.1) 318 (22.9) 444 (28.9) 0.001
increase in ics dose 2908 (7.3) 959 (9.8) 602 (8.9) – 320 (5.1) 75 (5.4) 104 (6.8) –
  Use of additional rx  
for asthma
3256 (8.2) 834 (8.5) 645 (9.5) – 1532 (24.5) 266 (19.2) 386 (25.1) –
Notes: Values shown are n (%). P-values for comparison among the three cohorts calculated with χ2 test for categorical data; aThe short-acting β-agonist dose is the albuterol 
dose equivalent (standard dose in UK is 100 µg).
Abbreviations: BAi, breath-actuated inhaler; DPi, dry powder inhaler; ics, inhaled corticosteroid; LrTi, lower respiratory tract infection; pMDi, pressurized metered-dose 
inhaler; sABA, short-acting β2 agonist.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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as patients may obtain extra prescriptions to have reliever 
therapy readily available in different places frequented 
during the day.
Our study limitations include those inherent to any obser-
vational study using retrospective data. While results were 
adjusted for multiple potential confounding factors, there 
remains the possibility of confounding factors not accounted 
for, such as particle size of ICS and lung deposition pro-
files, as well as factors that cannot be adjusted for, such as 
health-care professional preference; this can compromise the 
internal validity of the study. Moreover, our study data were 
recorded when CFC propellants were still in common use; 
there may be issues related to the newer hydrofluoroalkane 
(HFA) propellants that are not captured by this study. Thus, 
we consider our study results to be hypothesis-generating 
and suggest that they be interpreted in conjunction with find-
ings from RCTs, pragmatic trials, and other observational 
studies.
Conclusion
Results of this retrospective database study reflect real-world 
effectiveness of ICS via three different delivery devices 
and suggest that selection of inhaler device type has a 
bearing on clinical asthma outcomes. The odds of asthma 
control were mostly better, and severe exacerbation rates 
lower, for patients initiating or increasing ICS therapy via 
BAI or DPI rather than a pMDI. These differences among 
inhaler devices require closer evaluation in well-designed 
  prospective trials.
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